AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04573465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Coaching
Description: Participants receiving phone coaching receive one 10-15 minute phone call each week from their randomly assigned peer-support coach. During coaching calls, the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed, asking what the participant liked/disliked about the modules, etc.).
Study NCT04573465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Coaching
Description: Participants receiving text message coaching receive text messages on a weekly basis from their randomly assigned peer-support coach. Text messages from the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed).
Study NCT04573465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT Guide
Description: ACT Guide is an online self-help program based on acceptance and commitment therapy (ACT), targeting acceptance, mindfulness, and values-based processes. It is intended to be used for 20 to 40 minutes at time, a few times a week. While using ACT Guide, participants will read about concepts relevant to ACT and engage in guided experiential exercises, with additional exercises being assigned to be completed in between sessions as homework.
Study NCT04573465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Guide
Description: ACT Guide is an online self-help program based on acceptance and commitment therapy (ACT), targeting acceptance, mindfulness, and values-based processes. It is intended to be used for 20 to 40 minutes at time, a few times a week. While using ACT Guide, participants will read about concepts relevant to ACT and engage in guided experiential exercises, with additional exercises being assigned to be completed in between sessions as homework.
Study NCT01223157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological data
Description: Height, Weight, waist circumference and systolic and diastolic blood pressure will be measured in obese and normal subjects. Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch. This will allow a measurement of fasting glycaemia and insulin, fasting cholesterol and triglycerides, liver profile. Endocannabinoids will be measured both in plasma and saliva at each time point. Gut hormones (Ghrelin and PYY) will be measured before, just before and after lunch in plasma.
Study NCT01263951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: One 5 mg. tablet daily.
Study NCT01263951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 200 mg. twice daily.
Study NCT03102814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current rehabilitation
Description: The control group will receive the rehabilitation currently offered at each of the participating centers.
Study NCT03102814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The BRIDGE program
Description: The experimental group will additionally receive the BRIDGE program, which comprises motivational interviewing, structured goal-setting, tailored follow-up, plans for self-management, and individualised written feedback that participants can use to monitor their progress and share with important care givers.
Study NCT03045406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets
Study NCT03045406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: Injections
Study NCT04184193 — intervention group
Intervention type: OTHER
Intervention: Pulmonary Rehabilitation
Description: Patients will perform a comprehensive, inpatient pulmonary rehabilitation program for 4 weeks duration
Study NCT01550198 — intervention group
Intervention type: DEVICE
Intervention: Advanced hemodynamic monitoring
Description: Comprehensive advanced hemodynamic monitoring
Study NCT00136955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan (60mg/sqm, D1, 8, 15) Plus Cisplatin (60mg/sqm, D1) As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix
Study NCT04905394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subchondroplasty
Description: subchondroplasty is an innovative percutaneous procedure in which calcium phosphate, biocompatible material similar to the native bone apatite with osteoinductive properties, is injected inside BML areas. The purpose of subchondroplasty is the patient's symptoms relief, improving the mechanical strength of subchondral bone, stimulating bone remodeling to avoid bone sagging, and slow down the arthritic degenerative process to postpone arthroplasty.
Study NCT01477125 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Flex working memory training
Description: 30-40 minutes of working memory training, 5 days a week for 5 weeks
Study NCT01477125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flex working memory training
Description: 30-40 minutes of working memory training, 5 days a week for 5 weeks
Study NCT03016364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APP software
Description: A software used to by physicians to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain
Study NCT04225247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Bond Universal
Description: Single bond universal (by 3M ESPE) is a seventh generation bonding agents used as desensitizers in the present study.
Study NCT03464968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin,5FU, leucovorin
Description: mFOLFOX
Study NCT03464968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan,5FU, leucovorin
Description: mFOLFIRI
Study NCT02922348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy
Description: Hormone replacement therapy as indicated in Arm 1
Study NCT02922348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptives
Description: Combined oral contraceptives as indicated in Arm 2
Study NCT03230227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine magnesium
Description: bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
Study NCT03230227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine only
Description: bupivacaine 0.125% infusion in the presternum , for 48 hours
Study NCT03849274 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Smart Scar Care Pad=Pressure Garment
Description: Smart Scar Care Pad (SSCP) + conventional Pressure Garment in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
Study NCT03849274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Garment
Description: Conventional Pressure Garment (PG) alone in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
Study NCT03849274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure Garment
Description: Conventional Pressure Garment (PG) alone in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
Study NCT03031587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional MRI acquisition sequences
Description: It deals with specific sequences of rapid imaging acquisition in gradient echo (4 to 5 slices/cardiac cycle) with synchronization on the surface ECG systematically included in a cardiac MRI examination, together with update of the slice position depending on the respiratory state (established technique of navigator echo). The acquisition is repeated over 300 cardiac cycles to monitor myocardial temperature changes
Study NCT03031587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: cardiac MRI
Study NCT00610116 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electronic Repositioning
Description: Change of pacing vectors for CRT pacing
Study NCT01624038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea ,Epiao
Description: Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week.
Study NCT01624038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyurea, blood transfusion
Description: * Hydroxyurea was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued.
Study NCT02159248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid + gemcitabine + radiation
Description: Cohort 1: 200mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 2: 400mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 3: 600mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 4: 800mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).
Study NCT01770054 — intervention group
Intervention type: OTHER
Intervention: obtention of a blood sample
Description: a blood sample will be obtained to measure glucose, HDL cholesterol, triglycerides, and for genetic testing
Study NCT01877408 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgical circumcision
Description: Open surgical circumcision using a technique approved by the WHO (dorsal slit)
Study NCT01877408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unicirc device with tissue adhesive
Description: Removal of foreskin with Unicirc disposal device and wound sealing with tissue adhesive.
Study NCT00356148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin/Sulbactam
Description: Ampicillin/Sulbactam 1 gr, once within onr hour before surgery
Study NCT01930084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated ART initiation
Description: Accelerated ART initiation for eligible participants delivered by facility personnel
Study NCT02555150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063
Description: Oral extended-release capsule
Study NCT02555150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisdexamfetamine dimesylate
Description: Oral capsule
Study NCT02555150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule
Study NCT03326375 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Maximum dose : 60Gray (Gy) Fraction : 2 to 5
Study NCT03065868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
Description: H. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment
Study NCT03280173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: bioavailability study
Study NCT02555150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule
Study NCT00926471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) Program
Description: 12 to 14 weekly sessions of individual CBT and parent training with 5 sessions of group counseling every other week
Study NCT06250920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality visual training
Description: Children in intervention group were administered at home under the supervision of parents for 20 minutes per session every day with virtual reality visual training
Study NCT01830868 — intervention group
Intervention type: DRUG
Intervention: Zonisamide tablets
Description: The recommended initial daily dose is 50 mg in two divided doses. After one week the dose may be increased to 100 mg daily and thereafter the dose may be increased at weekly intervals, in increments of up to 100 mg. Doses of 300 mg to 500 mg per day have been shown to be effective, though some patients, especially those not taking CYP3A4 (cytochrome P450)-inducing agents, may respond to lower doses.
Study NCT01930084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS appointment reminders
Description: Cellular appointment reminders delivered by study personnel
Study NCT03600402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: 6 sessions of ankle manual therapy
Study NCT03600402 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: 6 sessions of placebo intervention
Study NCT04120233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo administered orally
Study NCT01930084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-cash Financial Incentives
Description: Non-cash Financial Incentives
Study NCT03097341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xisomab 3G3- Dose 1
Description: Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
Study NCT03097341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xisomab 3G3-Dose 2
Description: Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
Study NCT03097341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xisomab 3G3-Dose 3
Description: Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
Study NCT03097341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xisomab 3G3- Dose 4
Description: Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
Study NCT04383990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of taking insulin
Description: To take insulin Glargine early (6-7pm) or late (bedtime-10-12pm)
Study NCT04225247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bifluorid 12
Description: it is a fluoride varnish by VOCO.
Study NCT03097341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single intravenous dose of placebo.
Study NCT04120233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW151, 10mg
Description: 10 mg MW151, 1 x 10mg capsule administered orally
Study NCT04120233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW151, 20mg
Description: 20 mg MW151, 1 x 20mg capsule administered orally
Study NCT00861393 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT
Description: 12 Session CBT group
Study NCT00861393 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist CBT
Description: Participants in the waitlist will receive CBT when first group has completed CBT and been tested.
Study NCT02571101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDFR0812-15/25mg
Description: Contains chlomipramine HCl 15mg and sildenafil citrate 25mg.
Study NCT02571101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDFR0812-15/50mg
Description: Contains chlomipramine HCl 15mg and sildenafil citrate 50mg.
Study NCT02571101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Condencia
Description: Contains chlomipramine HCl 15mg.
Study NCT04225247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeno V+
Description: Xeno V+ (by Dentsply) is a seventh generation bonding agents used as desensitizers in the present study.
Study NCT03769129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study NCT03769129 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab
Study NCT02571101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CDFR0812-Placebo
Description: Placebo tablet of CDFR0812.
Study NCT02571101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Condencia-Placebo
Description: Placebo tablet of Condencia
Study NCT00786981 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Epidural steroid injection plus physical therapy
Description: Patients in the ESI+PT Group will be treated additionally with a physical therapy program emphasizing lumbar flexion exercises, aerobic and strength/ conditioning exercises, and manual physical therapy as well as receiving up to 3 epidural steroid injection(s) and educational support using The Back Book.
Study NCT00786981 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Epidural steroid injection
Description: Patients in the ESI Group will be treated with up to 3 epidural steroid injections, educational support, and general care by the treating physician.
Study NCT02792543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Entéromate™
Description: Chyme reinfusion (the experimental treatment) consists of continuously reinfusing the chyme collected from the proximal small bowel segment via the enterostomy, and into the diverted distal small bowel segment. It implies the use of the Entéromate™ pump.
Study NCT02792543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parenteral nutrition
Description: Parenteral nutrition (the gold standard treatment) consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
Study NCT04043533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises
Description: The women in the experimental group were given information about the benefits of exercises done in the postpartum period, the time to start these exercises, and the exercises to be conducted in three different phases (mild, medium, severe). The first physical exercise practice was done in the FHC together. In line with the recommendations by ACOG (2015), the women were told to do mild and medium level exercises in the first two weeks, at least five days in a week and at least half an hour daily (ACOG, 2015). They were also told that they should do medium and severe level exercises in the following two weeks. They were asked to mark on the form what time, how long, and at what level they did the exercises every day. The education booklet that included this information and the visuals of the exercises were given to the women in the experimental group. In addition, the women were called once a week in order to check whether the training was applied.
Study NCT03000998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web App Intervention Group
Description: All baseline and follow-up data collection will be conducted via online surveys and a customized web portal and include parent self-reports and clinic records of vaccination of boys
Study NCT03000998 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Customary Care Group
Description: Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on HPV vaccination from the Centers for Disease Control and Prevention (CDC) in Portable Document Format (PDF) format.
Study NCT01960816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procedure: thermal coagulation of tissue in the nasal airway
Description: The Vivaer Stylus is used to deliver low-power, temperature-controlled, radiofrequency energy to tissues of the nasal airway to cause coagulation of soft tissues and submucosal tissue shrinkage.
Study NCT04120233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW151, 40mg
Description: 40 mg MW151, 2 x 20mg capsule administered orally
Study NCT04120233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW151, 80mg
Description: 80 mg MW151, 1 x 80mg capsule administered orally
Study NCT04120233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW151, 160mg
Description: 160 mg MW151, 2 x 80mg capsule administered orally
Study NCT02683564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOW015
Description: monoclonal antibody against TNF-alpha
Study NCT02683564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: monoclonal antibody against TNF-alpha
Study NCT02147158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Description: Ulipristal acetate (UPA) tablet.
Study NCT01671787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-7340
Description: Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
Study NCT01466985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).
Study NCT01466985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets once daily for 7 days.